Supplementary Figure Legends from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 105K</p

Supplementary Figure 3 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 38K, Alternative comparative presentation of results presented in Figure 3 C-F.</p

Supplementary Figure 2 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 133K, Measurements of additional receptor ligands from conditioned media.</p

Supplementary Figure 4 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 118K, LIM1215 knocked-in with a KRAS G12R mutation are also capable of paracrine protection of sensitive wild type (wt) cells and secrete higher levels of TGFalpha.</p

Supplementary Figure 1 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 95K, Schematic representation of conditioned medium assay (CMA).</p

Supplementary Figure 2 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i>-<i>Ras</i> Mutant Colorectal and Pancreatic Cancers

PDF file - 1498KB</p

Supplementary Figure 4 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i>-<i>Ras</i> Mutant Colorectal and Pancreatic Cancers

PDF file - 204KB</p

Supplementary Figure Legend from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i>-<i>Ras</i> Mutant Colorectal and Pancreatic Cancers

PDF file - 70KB</p

Supplementary Methods, Tables S1 - S2 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer

Supplementary Table S1. List of genes and exons analyzed by targeted next-generation sequencing. Supplementary Table S2. Summary of molecular data from the ISH and sequencing analyses conducted on both the pre-treatment primary tumor and the liver biopsy obtained after progression on panitumumab plus vemurafenib treatment. List of abbreviations: IHC, immunohistochemistry; ND, not done; SISH, dual-color silver in-situ hybridization; FISH, fluorescence in-situ hybridization.</p

Supplementary Figure Legends from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer

Supplementary Figure Legends</p